1njs: Difference between revisions
From Proteopedia
Jump to navigationJump to search
New page: left|200px<br /> <applet load="1njs" size="450" color="white" frame="true" align="right" spinBox="true" caption="1njs, resolution 1.98Å" /> '''human GAR Tfase in ... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1njs.gif|left|200px]]<br /> | [[Image:1njs.gif|left|200px]]<br /><applet load="1njs" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="1njs" size=" | |||
caption="1njs, resolution 1.98Å" /> | caption="1njs, resolution 1.98Å" /> | ||
'''human GAR Tfase in complex with hydrolyzed form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid'''<br /> | '''human GAR Tfase in complex with hydrolyzed form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid'''<br /> | ||
==Overview== | ==Overview== | ||
Glycinamide ribonucleotide transformylase (GAR Tfase) has been the target | Glycinamide ribonucleotide transformylase (GAR Tfase) has been the target of anti-neoplastic intervention for almost two decades. Here, we use a structure-based approach to design a novel folate analogue, 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid (10-CF(3)CO-DDACTHF, 1), which specifically inhibits recombinant human GAR Tfase (K(i) = 15 nM), but is inactive (K(i) > 100 microM) against other folate-dependent enzymes that have been examined. Moreover, compound 1 is a potent inhibitor of tumor cell proliferation (IC(50) = 16 nM, CCRF-CEM), which represents a 10-fold improvement over Lometrexol, a GAR Tfase inhibitor that has been in clinical trials. Thus, this folate analogue 1 is among the most potent and selective inhibitors known toward GAR Tfase. Contributing to its efficacious activity, compound 1 is effectively transported into the cell by the reduced folate carrier and intracellularly sequestered by polyglutamation. The crystal structure of human GAR Tfase with folate analogue 1 at 1.98 A resolution represents the first structure of any GAR Tfase to be determined with a cofactor or cofactor analogue without the presence of substrate. The folate-binding loop of residues 141-146, which is highly flexible in both Escherichia coli and unliganded human GAR Tfase structures, becomes highly ordered upon binding 1 in the folate-binding site. Computational docking of the natural cofactor into this and other apo or complexed structures provides a rational basis for modeling how the natural cofactor 10-formyltetrahydrofolic acid interacts with GAR Tfase, and suggests that this folate analogue-bound conformation represents the best template to date for inhibitor design. | ||
==About this Structure== | ==About this Structure== | ||
1NJS is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with PO4 and KEU as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phosphoribosylglycinamide_formyltransferase Phosphoribosylglycinamide formyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.1.2.2 2.1.2.2] Full crystallographic information is available from [http:// | 1NJS is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=PO4:'>PO4</scene> and <scene name='pdbligand=KEU:'>KEU</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phosphoribosylglycinamide_formyltransferase Phosphoribosylglycinamide formyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.1.2.2 2.1.2.2] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1NJS OCA]. | ||
==Reference== | ==Reference== | ||
| Line 15: | Line 14: | ||
[[Category: Phosphoribosylglycinamide formyltransferase]] | [[Category: Phosphoribosylglycinamide formyltransferase]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Benkovic, S | [[Category: Benkovic, S J.]] | ||
[[Category: Boger, D | [[Category: Boger, D L.]] | ||
[[Category: Desharnais, J.]] | [[Category: Desharnais, J.]] | ||
[[Category: Gooljarsingh, L | [[Category: Gooljarsingh, L T.]] | ||
[[Category: Hedrick, M | [[Category: Hedrick, M P.]] | ||
[[Category: Li, C.]] | [[Category: Li, C.]] | ||
[[Category: Marsilje, T | [[Category: Marsilje, T H.]] | ||
[[Category: Olson, A | [[Category: Olson, A J.]] | ||
[[Category: Tavassoli, A.]] | [[Category: Tavassoli, A.]] | ||
[[Category: Wilson, I | [[Category: Wilson, I A.]] | ||
[[Category: Zhang, Y.]] | [[Category: Zhang, Y.]] | ||
[[Category: KEU]] | [[Category: KEU]] | ||
| Line 30: | Line 29: | ||
[[Category: protein-cofactor analogue complex]] | [[Category: protein-cofactor analogue complex]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:06:51 2008'' | ||